2025-03-31-accounts

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

Company no. 01902326 Charity no. 291714

Bristol Drugs Project Limited Report and Audited Financial Statements 31 March 2025

Bristol Drugs Project Limited

Contents
For the year ended 31 March 2025
	Page
Reference and administrative details	1 - 2
Trustees' report	3 - 17
Independent auditors’ report	18 - 21
Statement of financial activities	22
Balance sheet	23
Statement of cash flows	24
Notes to the financial statements	25 - 47

Bristol Drugs Project Limited

Reference and administrative details

For the year ended 31	March 2025
Company number	01902326
Charity number	291714
Registered office and	11 Brunswick Square
operational address	Bristol
	BS2 8PE
	Tel: 0117 987 6000
Trustees	The trustees who served during the year and up to the date of this report
	were as follows:
	K Barker
	D Bradnock
	K Curling
	P Godfrey
	G Henderson
	M Lea, BA Hons, FCA, CTA
	R Paine
	T Rice (Chair)
	T Smyth MRCGP FRCS
	M Wilkinson
	T Bale	(appointed 11/11/2024)
	H Colton	(appointed 11/11/2024)
	L Hansford	(appointed 11/11/2024)
	J Long QPM, BA Hons, MA	(resigned 11/11/2024)
	J Risk	(resigned 11/11/2024)
	R Mayall	(resigned 13/01/2025)
Senior management	Kathryn Talboys	Service Manager (resigned 30/6/2024)
team	Anna Smith	Chief Executive Officer (resigned 24/12/2024)
	Benjamin Judd	Director of Business Development (resigned
		31/12/2024)
	Lydia Plant	Director of Operations (until 11/12/2024),
		Interim Chief Executive Officer (appointed
		11/12/2024), Chief Executive Officer
		(appointed 1/4/2025)
	Karen Black	Interim Management Support
Bankers	Unity Trust Bank plc	Triodos Bank
	Nine Brindleyplace	Deanery Road
	4 Oozells Square	Bristol
	Birmingham	BS1 5AS
	B1 2HB
	Cambridge & Counties Bank
	Charnwood Court
	5B New Walk
	Leicester
	LE1 6TE

Bristol Drugs Project Limited

Reference and administrative details

For the year ended 31 March 2025

Solicitors Shakespeare Martineau Veale Wasbrough Vizards LLP One Temple Quay Narrow Quay House Temple Back E Narrow Quay Bristol Bristol BS1 6DZ BS1 4QA Investment managers Cazenove Capital Schroder & Co. Limited 1 London Wall Place London EC2Y 5AU Auditors Godfrey Wilson Limited Chartered accountants and statutory auditors 5th Floor Mariner House 62 Prince Street Bristol BS1 4QD

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

The Trustees who are also directors of the charity for the purposes of company law, present their annual report together with the financial statements of the charity for the year ended 31 March 2025.

Reference and administrative information set out on page 1 forms part of this report. The financial statements comply with current statutory requirements, the Memorandum and Articles of Association and the Statement of Recommended Practice - Accounting and Reporting by Charities (effective from January 2019).

Structure, governance and management Governing document

Bristol Drugs Project is a charitable company limited by guarantee, incorporated on 3rd April 1985 and registered as a charity on 14th May 1985. The company was established under a Memorandum of Association that founded the objects and powers of the charitable company and is governed under its Articles of Association. The Directors completed their review of the Memorandum and Articles of Association to ensure that, as well as being compliant with the Charities Act 2011 and Companies Act 2006, they are relevant to current patterns of drug and alcohol use, and contemporary policy.

In the event of the company being wound up, members are required to contribute an amount not exceeding £10 each.

Board of Trustees (Directors)

The Directors of the company are also charity trustees for the purpose of charity law and under the company’s Memorandum and Articles of Association, are known as members of the Board of Trustees. The Board of Trustees can have a minimum of three members.

The Board are very active, meeting approximately every six weeks. They are responsible for the strategic direction and policy of the charity, and for ensuring that its finances, systems and procedures are ‘fit for purpose’. The Board of Trustees delegates operational management of the charity to a Chief Executive Officer, who in turn delegates responsibility for specific areas of service delivery, performance, and staff and volunteer management to senior managers.

Trustees bring a wide range of business and professional skills to their role and adhere to the ‘Nolan Principles’ for public office holders. The involvement of former service users as trustees is particularly important, ensuring the needs of beneficiaries of the charity are at the core of BDP policy and strategy.

At the year-end, the Board of Trustees had 13 members from a variety of backgrounds relevant to the charity and its management.

Recruitment, appointment and changes to Board of Trustees

The charity operates a competency-based recruitment process, recruiting new Board members as required. Prospective Board members are interviewed by a panel of trustees and invited to observe a Board meeting. The Board of Trustees then decides whether to invite a new member to join them and to stand for election at the next Annual General Meeting (AGM).

The Memorandum and Articles require a third of the membership of the Board to retire annually, although trustees may stand for re-election at the next AGM.

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

BDP seeks to achieve a balance between longer-serving trustees who use their expertise and ‘collective memory’ to provide continuity to BDP’s work, and newly recruited trustees who bring fresh skills and perspective to the charity.

Board of Trustees induction and training

All applicants for the Board of Trustees receive a Recruitment Pack which gives a role description of their obligations as Board members together with information about the charity. All are given the Charity Commission’s guide ‘The Essential Trustee’ together with a copy of BDP’s Memorandum and Articles of Association and the latest financial statements. New members are encouraged to shadow services, and to participate in the charity’s annual service planning and review day and in-house training; this enables them to gain an in-depth understanding of the charity’s main activities to inform their decision-making.

Board of Trustees’ committees

At the end of 2023-24, a working party of Trustees conducted a review of organisational governance and initiated a new Committee structure. The Board of Trustees now has three Committees. The Board has the power to delegate decision-making to these Committees.

Firstly, the Charity’s Finance and General Purposes Committee meets every six weeks to review financial performance, recommend any actions necessary to control financial risk, ensure service delivery within budget and agree significant capital expenditure.

Secondly, the People Committee meets quarterly to review all aspects of performance linked to people, HR, Safeguarding, and ED&I. This Committee takes responsibility for the development of, and adherence, to all relevant policies.

Finally, the Quality and Performance Committee meets quarterly to ensure adequate and appropriate governance structures, processes and controls are in place throughout BDP. This Committee ensures that BDP operations promote safe, high-quality care and ensure the effective and use of resources through evidence-based practice and research. It also ensures that BDP reports appropriately to funders.

Senior Leadership Team (SLT)

During 2024/25, this comprised Anna Smith (Chief Executive Officer), Lydia Plant (Director of Operations), Ben Judd (Director of Business Development) and Karen Black (Interim Management Support).

Anna Smith resigned as Chief Executive Officer (CEO) in December 2024, with Lydia Plant moving into the role of Interim CEO in December 2024 and then being appointed as permanent CEO in March 2025. Ben Judd resigned from his post in December 2024; the SLT has reviewed the role of Director of Business Development and will recruit to a slightly adapted role in 2025-6.

The SLT are responsible for delivering BDP’s Strategic Plan. Operational decisions are made by the SLT at weekly meetings. Regular meetings of the Senior Management Team, which includes Team Leaders, ensure effective communication and planning and support the development of managerial capacity and competency of Team Leaders.

The Board of Trustees and SLT declare potential conflicts of interest to BDP annually, or when their circumstances change. Conflicts of interest relevant to the business of meetings are sought by the Chair of those meetings and declared as a standard agenda item at all such trustee meetings.

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Partnership working

Partnership working, including through formal partnerships, collaboration with other organisations, and link workers, is an integral part of BDP’s values and approach.

Bristol’s drug and alcohol services underwent recommissioning during 2024-5. BDP sought a partner with which to bid for the contract, forming a partnership with Turning Point, a national health and social care charity with expertise in substance use treatment as well as learning disabilities, sexual health and mental health. We are proud that this partnership was successful in winning the contract to implement the new service, named Horizons Bristol, from 1 April 2025. The Horizons Bristol partnership incorporates seven other organisations which bring wider expertise: One25, Hawkspring, Wellspring Settlement, the Southmead Development Trust, the Southmead Project, Release, and The Nelson Trust.

BDP also deepened our partnership with Turning Point by supporting their bid to deliver drug and alcohol treatment services in Bath and North East Somerset (BaNES) as sub-contractors. This bid was also successful and BDP is thrilled to be bringing our expertise around harm reduction and working with young people to this contract, beginning on 1 April 2025.

In 2024/25, BDP worked in partnership with Next Link with a joint worker who supported the substance use related needs of women using drugs and alcohol in a Next Link complex needs safehouse for women fleeing domestic abuse. BDP also continued a long-standing relationship with Second Step by appointing to a joint role in the Link Team, with the worker supporting individuals who were homeless and experiencing multiple barriers to accessing mental health and substance use treatment. At the end of the financial year, BDP finalised plans to employ a specialist drug and alcohol worker to be placed in St Mungo’s Street Outreach team, looking to make treatment more accessible to those experiencing street homelessness. This new role is funded by Public Health and will have a focus on cross-system partnership working.

BDP were also proud to continue our partnership with Stand Against Racism and Inequality (SARI) who provided their expertise around Equity, Diversity and Inclusion at BDP. BDP has continued to work on becoming a charity more representative of our community and growing in our understanding of how we can do better at serving those who face barriers to accessing our treatment. SARI provided 9 sessions of EDI training, as well as supporting the EDI working group. This working group has focused on building links with other community organisations and exploring how areas such as BDP’s recruitment can be improved to reduce barriers and encourage applications from a wider range of people. Lastly, we were thrilled to welcome Tia Bale, a member of staff at SARI, to our Board, cementing the relationship further.

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Risk management

The Board of Trustees considers and approves a risk map and management plan each year, which identifies the risks to which BDP may be exposed. The methodology used to assess risk evaluates these on a five-point scale of likelihood of occurrence and a five-point scale of impact. Mitigation measures are reviewed, and a post-evaluation score agreed with retained risks categorised as red, amber or green. The Chief Executive, supported by the Senior Leadership Team, maintains a risk register, which is reviewed by the Board at each Board meeting, and a financial risk register that is reviewed at every Finance and General Purpose Committee. These documents allow BDP trustees and senior leaders to highlight and track risks to the charity and monitor the mitigation of these risks.

In 2024-5, the biggest risk for BDP as a charity was losing the bid for the Bristol drug and alcohol treatment service, which would have posed a significant threat to BDP’s income, ability to meet our charitable objectives and would have resulted in around 85% of BDP’s staff being transferred (TUPE’d) to other organisations or being made redundant. Therefore, a huge amount of work was undertaken to mitigate this risk and ensure that our tender was successful.

In 2025-6, the main risks to BDP include:

Loss of funding – discussed further in Section 5;
Issues with service - Horizons is an exciting new partnership for BDP and the city of Bristol, however as with any partnership, were our levels of service quality or effectiveness to drop, we would be exposed to significant risk. As noted in last year’s report, the partnership commissioning model, while much needed to address challenges in previous commissioning models, necessitates significant change to BDP operations and structure. We are reviewing our policies and procedures to ensure they are up-to-date, legally compliant and facilitate our staff to deliver an ongoing high standard of service;
Reputational – while BDP continues to be viewed positively by service users, professional colleagues and commissioners, there is always a potential for reputational risk should significant incidents occur or should perceptions of BDP change. We continue to monitor reputational risks via the overarching risk register; and
Business continuity risks – we maintain a plan for emergency response and for business continuity in the event of an emergency.

Objectives and activities Charitable purpose

Bristol Drugs Project’s (BDP) charitable purpose is described in the objects within the Charity’s Memorandum and Articles of Association as:

the relief of poverty, sickness and distress among people affected by the use of alcohol or drugs of any kind or otherwise in need;
the advancement of education, training and research arising from the use of alcohol or drugs, together with the publication of the results of any such research; and
the prevention of harm from alcohol or drug use and to make provision for the treatment and care of those affected by alcohol or drug use.

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Achievements & performance – delivering public benefit

This report describes how the charity’s activities fulfil the Public Benefit provisions of the Charities Act 2011. In doing this, the charity has complied with the duty in section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission. The Board of Trustees is satisfied that BDP has charitable aims that are carried out for public benefit, specifically:

The benefits to individuals, families and communities (and hence to the public) are clear and in line with BDP’s aims;
The beneficiaries are entirely appropriate to BDP’s aims;
BDP has no unreasonable restrictions on access to our services either by poverty, a requirement to pay fees, geographic restriction or provision of services restricted to certain sections of the public, as all services are free at the point of delivery; and
Only beneficiaries benefit from BDP’s activities; there is no ‘private benefit’.

This report describes BDP’s activities transparently, documenting their relevance to our objects as a charity and demonstrating that BDP’s activities are effective in achieving the charity’s aims. BDP has reviewed any potential negative impact of its activities to satisfy itself that the benefits far outweigh any detriment or harm arising from the charity’s activities.

Who we provide public benefit for

BDP delivers services to individuals, families, and communities affected by drug and/or alcohol use, which reduce harm, maximise individuals’ potential and promote independence from drugs and alcohol.

How we provide public benefit

10th March 2025 marked thirty-nine years of providing services. We continued to provide a wide range of interventions for people experiencing problems with alcohol or drugs, of all ages including children, at all stages of the complex process of behavioural change.

The services we provide are person-centred and tailored to individual need and choice - not dictated by our team’s personal beliefs or a ‘one size fits all’ approach. BDP’s role is to support people in building their recovery capital (rewarding relationships, valued activity, adequate housing, and income). Our approach is to support, not judge; recognise the impact of Adverse Childhood Experiences (ACEs) with trauma-informed approaches; nurture change with passion and ambition; and enable people to acquire skills and self-belief, which makes recovery an enduring and rewarding reality.

Harm reduction is a vital part of our work, and we continue to deliver a range of services to reduce the harms associated with drug and alcohol use, informed by input from our service users wherever possible. In 2024-5 these included:

Our advice centre, which is open to all and operates at 11 Brunswick Square from 9am to 5pm Monday to Friday and from 9am to 1pm on Saturday. Service users can receive harm reduction advice and have a safe space where they are supported. If appropriate, they can be referred to other services and seen by a nurse. Harm reduction advice is also available over the phone or by email to those who prefer these methods, as well as being promoted via our social media as appropriate;
Continuation of The Loop, England’s first regular drug checking service, hosted in Brunswick Square on the last Saturday of every month. The Loop staff undertake substance analysis and targeted consultations while BDP staff host the service and provide wider harm reduction advice;

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Our Needle and Syringe Programme, providing clean equipment and harm reduction advice, delivered at our advice centre and at approximately 20 participating pharmacies across Bristol. In 2024-5 we undertook a review of our needle exchange, with service users serving on the panel, and received funding to renovate the fixed site exchange at 11 Brunswick Square;
Support for people to register with NSP Direct so they could receive free equipment to their home, via the Exchange Supplies web shop;
Increasing the supply of Naloxone and training people across the city to administer Naloxone to reduce fatal overdoses, including appointing a Strategic Overdose Prevention Coordinator to lead on plans for reducing overdoses across the city;
Our nursing service - provided in collaboration with AWP and BrisDoc – including physical healthcare service to enable skin and soft tissue infections and other healthcare needs to be tackled early to reduce the risk of hospitalisation and harm. Our nurses and BDP staff also led work on micro-elimination of Hepatitis C (described in section 4);
Regular outreach to local homelessness pathway providers and supported housing;
Three Wet Clinics, which support those who are drinking dependently to get appropriate medical support, delivered in partnership with the Homeless Health Service; and
Outreach and harm reduction advice at local festivals, such as Love Saves the Day.

Alongside harm reduction, we deliver services which support individuals to connect or reconnect with their family and communities and pursue wider opportunities in their lives. We also support service users to maintain their chosen changes to drug and alcohol use, whether that is abstinence or more controlled use; these wider services also include opportunities for harm reduction. In 2024-5 these included:

Our Shared Care programme continued to be delivered in partnership with all but one of Bristol’s GP practices, and with approximately 1600 service users (the number varying throughout the year as service users entered or left treatment). Shared Care workers work alongside GPs to support service users to begin and maintain opiate substitution therapy (OST). A community detoxification link programme continued to run throughout 2024/25 to support service users to reduce and stop their prescriptions where appropriate. Shared Care appointments also offer an opportunity for harm reduction, and Shared Care workers played a significant role in reaching micro-elimination of Hepatitis C through carrying out tests for blood-borne viruses with service users;
Our Creative Communities continued to thrive, using new funding to employ a promotional worker. Creative Communities hosted a sold-out 10-year anniversary gala in October 2024 which received significant media attention including on BBC Points West. New groups were formed covering movement (Recovery in Motion) and lyric writing and food growing (Hip Hop Garden). In recognition of the valuable services provided to the community, Creative Communities received an award from the High Sheriff of Bristol;
Our 50+ social group went from strength to strength, offering two weekly gatherings on Wednesday and Friday afternoons, alongside monthly coffee mornings on Saturdays. Our 50+ worker also helped group members to access wider support as appropriate;
Our weekly Women’s Morning, run on Wednesdays with a crèche attached, continued to provide a valuable space for women to connect and enjoy a range of activities;
Our LGBTQ+ service Prism continued to meet weekly on Thursdays, moving from a group to a one-to-one support model, following which we saw a rise in service users accessing this service for support and harm reduction advice around substance use;

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Our Link Workers continued their work with particular groups or communities, supporting their pathways into treatment. This included workers focusing on diverse communities, complex and recurrent circumstances around homelessness; mental health or learning disabilities, people affected by domestic violence, people engaged with Families in Focus; and those requiring access to respiratory and renal health services; and
Our team continued to support those who had been identified as having problematic substance use and anti-social behaviour by our specialist anti-social behaviour workers.

Our specialist team also continued to deliver services for children and young people, both those using substances themselves and those affected by parental substance use. This included:

Delivering targeted interventions with young people (both those using substances themselves and those affected by parental substance use);
Delivering New Leaf and New Leaf Rapid services, working to support young people who are vulnerable to child criminal exploitation in the drugs market, and seeing secondary school students who have been found in possession of banned substances as an alternative to them being excluded;
Continuing to offer space for people aged between 5 and 16 affected by parental substance use through our two M32 youth groups (the groups split into younger and older children);
Continuing Intensive Family Support service, which works with families where there are parents who have a problematic relationship with drugs and/or alcohol and there is a Child Protection Plan or Child in Need plan in place. Through weekly home visits the service helps parents to identify and work with the strengths within the family, whilst exploring their relationship with drugs and/or alcohol and the benefits of staying in treatment;
Family help Link workers continuing to work within the Family Help Hubs (previously known as Families in Focus) to support clients that are struggling with their alcohol and/or substance use, by offering targeted sessions and referring into structured treatment. Additionally, our Link workers continued to offer consultations, support and training to family support workers and social workers within the hubs regarding supporting clients who use drugs and/or alcohol; and
Continuing to deliver Bristol’s Youth Alcohol & Drug Diversion (YADD) project, which offers young people found in possession of a substance for the first time to receive an education session with a BDP youth worker instead of receiving a warning or caution. Participants can then be referred for further support as necessary.

All of the charity’s services are free at the point of delivery. They are provided at multiple locations, including 42 GP surgeries, youth and family centres, and through extensive outreach to ensure easy access for those that require different approaches. Our Mobile Harm Reduction Service vehicle, our premises at Brunswick Court and our partner premises are compliant with the building provisions of the Disability Discrimination Act.

Research partnerships:

Supporting academic research and continuing to contribute to the evidence base around substance use has continued to be a focus for BDP in 2024-5. We entered the last phase of a three-year long research project conducted with the London School of Hygiene and Tropical Medicine into Safe Inhalation Pipe Provision (SIPP), an intervention to reduce health harms and enhance service engagement among people who use crack cocaine in England. This year, with a special dispensation from Avon and Somerset Police, we distributed thousands of Safer Inhalation Pipes and completed over 700 surveys of people who use crack. This research has begun to be published and has already begun to significantly influence the national conversation about the benefits of decriminalising the supply of safer inhalation devices, as well as understanding the health needs and motivations of people who use crack.

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

BDP partnered with the University of Bristol and other local women’s organisations, One25 and the Nelson Trust, to undertake research about the barriers women face in accessing harm reduction and treatment services in Bristol. This study, funded by NIHR and the Health Innovation Fund in Bristol, produced hyper-local feedback and recommendations from women whose voices are often not heard. BDP looks forward to working with One25 and the Nelson Trust to implement these recommendations for women as part of Bristol Horizons in 2025-6.

In September 2024, BDP collaborated with Tom May of the University of Bristol’s Health protection Unit to research the experience of local men who have sex with men (MSM) and engage in chemsex. This work will be completed in 2025-6 and will produce a set of harm reduction messages codesigned by researchers and men who engage in chemsex. This research partnership will add further value to PRISM, our LGBTQ+ treatment service and will ensure our messaging continues to be relatable, evidence-based and amplifies the voices of those who use drugs.

A member of staff and several service users have been a part of a collaboration with the University of Bristol to understand people's experiences of stigma in the context of collecting opiate substitution therapy (OST) medication from their pharmacy, called ‘Nothing about us, without us.’ We have taken part in a variety of co-produced workshops and have produced a set of recommendations for pharmacies which were implemented at the end of 2024.

BDP are a key contributor to the unlinked anonymous monitoring (UAM) surveys of people who inject drugs (PWID). This aims to measure the level of HIV, hepatitis B and hepatitis C in this population by taking anonymised blood samples. They also monitor the levels of risk and protective behaviours in this population. The surveys provide data on people who inject psychoactive drugs (such as heroin) and also on people who inject image and performance enhancing drugs (IPEDs). This year, BDP was once again in the top 5 of recruiting organisations across the UK.

We continue to regularly engage with a range of researchers and look forward to growing these relationships in the coming year.

Achievements and performance

We were pleased and proud to register a number of significant achievements in 2024-5. This section describes some of those achievements and provides some context for BDP’s performance against key success criteria.

10 years of Creative Communities

In October 2024, Creative Communities, Bristol Drugs Project’s flagship arts-based recovery initiative, celebrated their 10th Anniversary with a sold-out 150-capacity Gala at Circomedia, St Paul’s. The event marked a decade of weekly creative groups for people with lived experience of drug and alcohol use;
The programme featured inspiring performances by all major groups: Rising Voices Recovery Choir, Bristol Recovery Orchestra, Oi Polloi Theatre, Changing Tunes Beginners, Hip Hop Garden and Recovery in Motion. Highlights included acapella singing, orchestral adaptations of songs from John Williams and Cat Stevens, hip hop, a funk medley, and a striking finale with spoken word and movement. We were grateful to feature guest appearances from Bournemouth Symphony Orchestra musicians and vocal support from The Fitzhardinge Consort and Gasworks Choir. The gala also hosted the launch of Pete Weinstock’s poetry collection Between the Cracks, dedicated to BDP’s late cofounder Maggie Telfer; profits from book sales were donated to BDP services;

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Local and national media attention included pre- and post-gala coverage from BBC Online, BBC Points West, Bristol 24/7, Ujima Radio, Performing Recovery, and BCFM. The gala received a particularly positive review in Bristol 24/7, praising the evening as an “inspiring night of healing and triumph” through music and performance;
Alongside this landmark performance, Creative Communities put on other performances throughout the year including seasonal showcases and singing at commemoration events. Throughout 2024-5, Creative Communities groups had approximately 60 individuals engaged in groups including the Rising Voices choir, Bristol Recovery Orchestra, and Changing Tunes beginners’ group, with some service users being engaged in multiple groups; and
Finally, Bristol Sober Spaces (a partnership which BDP Creative Communities is part of) hosted sold-out hip-hop and metal nights and launched a new website to spread awareness, with more exciting events planned for 2025-6.

The Transformation Programme

BDP received funding for 2024/25 from Bristol City Council to carry out the Transformation Programme. This funding enabled BDP to hire 18 new staff on fixed-term contracts until March 2025 including new alcohol early intervention and assessment teams, seven new Shared Care workers, administrative workers, and a transformation lead. The aim was to tackle some of the most significant and entrenched issues in Bristol’s drug and alcohol treatment and strengthen links between GP practices and treatment providers;
At the end of 2023-24 as part of the Transformation Programme, BDP staff created a new online booking system which enabled GPs to refer clients seeking drug and alcohol treatment for an appointment with a BDP worker. BDP also started a self-referral service (online or phone) for anyone in the city who was seeking support with their alcohol use. These new systems had several benefits, including that GPs could give their clients an assessment appointment time on the spot rather than a worker having to follow up with the client, and that the client could be seen in the surgery, at BDP or on the phone as appropriate;
The assessment team assessed any client referred for drug and alcohol treatment from any of the 42 participating GP surgeries located in the Bristol council area (in some cases clients were assessed by Shared Care workers or the early intervention alcohol service, since they would likely also be treated by these teams). The team maintained a steady flow of assessments throughout the year, with a peak of 151 people being assessed in October 2024. This contributed greatly to a rise in the number of people receiving drug and alcohol treatment in Bristol, which in 2024/25 reached the highest it had been for a decade;
The alcohol early intervention team assessed people who self-referred through BDP’s website or helpline, plus people referred by GPs who fit the service’s criteria. If suitable, the team offered clients three to five one-to-one appointments over a period of a few weeks to help them understand and set their goals for changing their substance use, understand triggers and develop strategies for reducing their use as wanted. If clients did not meet the service criteria (for example because they were drinking dependently), they were referred for treatment at other agencies within the city. 571 people were referred by healthcare professionals, or referred themselves, into this service in 2024-5. Although a higher than expected proportion of those assessed were drinking dependently and therefore not suitable for this scheme, 161 people did go on to take part in this ‘brief intervention’ treatment in 2024-5;
Shared Care workers offered assessments in surgery for opiate substitution therapy (OST) and GP-led alcohol detoxes, carrying out assessments alongside their regular Shared Care appointments. This enabled clients to be seen in their surgery rather than having to travel to BDP, and significantly reduced waiting times for to just a few days, as opposed to 4-6 weeks as they had been for OST before the transformation work. The average (median) waiting time for clients from referral to assessment was between 2 and 3 days across 2024-5;

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

A new system for managing and following up with clients who did not attend their assessments, devised by a BDP staff member, enabled the team to significantly reduce the ‘attrition rate’ (the rate of clients who were referred for treatment but dropped out of treatment before receiving an assessment). The overall rate was consistently at around 20% throughout the first three quarters, rising in Q4. Attrition rates for drug and alcohol treatment services between referral and assessment tend to be between 30-40% and sometimes higher, so this is an outstanding achievement by the staff who delivered or supported assessments; and
GPs' feedback on this new system was highly positive, with a survey conducted near the end of 2024-5 giving an average GP satisfaction score of 8.6 out of 10, and one GP describing the system as ‘genius’! The system has been retained for Horizons, enabling more efficient and deeper links between GP practices and the drug and alcohol service. Service user feedback (from conversations and surveys conducted with those assessed and treated by BDP) was also very positive. For example, over half of Shared Care service users surveyed rated their relationship with their Shared Care worker at the highest possible score (5 out of 5), with the average rating being 4.1 out of 5.

BDP staff are to be congratulated for their hard work and outstanding achievements through the Transformation Programme, including those working directly on the relevant services but also all those across BDP who have contributed. This work has made a significant contribution to tackling some of the longstanding challenges in Bristol’s drug and alcohol treatment and setting a positive foundation for Horizons services to build on.

Increasing rollout of Naloxone across Bristol

Bristol City Council’s Public Health funding enabled us to employ a Strategic Overdose Prevention coordinator in 2024-5. This extra resource allowed BDP to accelerate our efforts to roll out Naloxone across Bristol, in the face of national rising opioid overdose deaths. Distributing naloxone is a huge part of our service. It is a medication that can temporarily reverse the effects of an opioid overdose, giving emergency services more time to respond. From April-December 2024 alone we distributed a total of 2,647 doses of Naloxone (1,995 Prenoxad injectable doses and 652 Nyxoid nasal sprays); and
We also provide naloxone training for anyone who may work with, support, or interact with people who use drugs. This year we have trained over 800 individuals to be able to identify an opioid overdose and administer naloxone. Training as many people as possible is even more impactful for the community given the rise in synthetic opioids over the last few years.

Reaching Hepatitis C Micro-Elimination Status

In 2024 BDP achieved a major milestone: the micro-elimination of Hepatitis C in Bristol. This significant public health success was the result of a concerted, organisation-wide effort to increase access to Bloodborne Virus (BBV) testing for people who use our services. Hepatitis C microelimination in a drug service means the service has achieved:

100% of people who access the service have been offered a test;
100% of people who access the service with a history of injecting drugs have had a test;
90% of people in structured treatment with a history of injecting drugs who are at risk have had a test in the last 12 months; and
90% of people have started treatment, completed treatment, or cleared the virus naturally.

With a focused drive on Hepatitis C, this year marked our highest testing numbers to date, with over 1,050 BBV tests carried out—more than in any previous year. This achievement reflects our ongoing commitment to removing barriers to healthcare for some of the most marginalised members of our community.

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Collaboration with Dentaid

In collaboration with dental health charity Dentaid and kindly funded by BrisDoc, BDP offered dental appointments from Brunswick Square for people engaged in BDP services. Participants received a check-up, discussed any dental issues they were having and had emergency procedures, including fillings and extractions as needed;
This year we had 464 treatments covering 108 patients, including 79 extractions and 36 fillings; and
This collaboration with Dentaid and Brisdoc allows our service users to access dental healthcare, something that may not be possible without access to this service.

Key performance data

1,759 people were in structured treatment with BDP on 31 March 2025 (the total number of people receiving support from BDP was higher, however we do not track every visitor to the advice centre, so do not have an exact number for this);
1,954 people were referred in to BDP for an assessment in 2024-5 (by a healthcare professional, treatment provider, outreach, employment, social care or self-referral), with 1,472 assessments completed;
Median waiting times between referral and assessment were consistently at between 2 and 3 working days throughout 2024-5;
The needle exchange at 11 Brunswick Square completed 3,913 exchanges and 93 assessments, with 498 unique individuals using the needle exchange (it is not possible for us to track outcomes at each pharmacy which offers needle exchange);
Over 2,500 doses of Naloxone (injectable and spray) were distributed with over 800 service users, professionals and third parties trained – third parties able to distribute naloxone themselves after completing training and signing a service-level agreement with BDP;
161 people received structured support from the alcohol early intervention team, with 110 completing the course of one-to-one sessions (some of these participants decided not to take up the full course of sessions as they had already achieved their goals);
1,050 blood borne viruses (BBVs) tests were carried out, a record for BDP; and
As of February 2025, the average Shared Care worker caseload was 53, below the maximum target caseload of 60, meaning Shared Care workers were able to devote more time to each service user on their caseload.

Financial review

The operating environment has been challenging, including constraints on public expenditure, but BDP has continued to adapt to these changes and financial performance remains strong. The net financial result for the year shows surplus funds of £270,058. This compares with a surplus of £69,010 in the previous year. This surplus has been achieved by increased income of £1,089,599 for additional ROADS contracts linked to Bristol ROADS Substance Use Supplementary and Rough Sleepers Grants and by reduced expenditure over the period of 7 years on the ROADS contracts, which Bristol City Council have agreed for BDP to transfer to General Funds to further the charity’s objects for future use.

The accumulated funds at the year-end totalled £4,366,187 (2023/24: £4,096,129): ▪ Restricted funds £25,966 (2023/24: £339,630); and
Unrestricted funds £4,340,221 (2023/24: £3,756,499).

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Principal funding sources

Income received in 2024/25 was £5,651,838 (2023/24: £4,562,239).

Of the full year’s income, £1,065,612 (2023/24: £998,164) was paid to partners for sub-contracted service delivery, including payments to community pharmacies for delivery of Needle and Syringe Programmes, and to other sub-contractors Avon and Wiltshire Partnership (AWP) NHS Trust and BrisDoc Health Care.

The Board of Trustees would like to express its thanks to all the organisations that have provided funding, in particular Bristol City Council, which remains BDP’s largest funder.

Investment policy

The charity Trustees are responsible for making investment decisions, including approving the investment policy, setting the investment objectives, and selecting investment managers. Our investment manager, Cazenove, are responsible for implementing our investment strategy, reporting on investment performance and follow our ethical standards. They must act in our best interests and manager our investments prudently.

Our investment objectives are to achieve growth and income. We aim to generate sustainable returns that allow us to achieve our charitable objectives while protecting the capital value of our investments. We recognise that every investment carries risk, and we manage these risks to ensure that they are commensurate with our objectives and the financial resources available. BDP’s risk appetite is moderate, and we are willing to accept fluctuations in the value of our assets in pursuit of our investment objectives.

BDP will balance risk and return to achieve our investment objectives. We will seek to achieve our investment goals through a mix of investments with different risk profiles to achieve a diversified portfolio of investments that suit our needs. As stated above, we will balance the risk of lower returns versus the risk of damaging reputation, financial stability or alienating support.

We invest our financial resources in line with our objectives, risk appetite, and investment policy. The amount we have available for investment is reviewed by the Finance and General Purposes Committee throughout the year. However, our investment time horizon is long-term, and we aim to invest in funds for the long term. We recognise that investing is a long-term activity that requires a disciplined approach to generate sustainable returns.

We will ensure that our charity has sufficient liquidity to meet our financial commitments, including grants and other charitable activities. We will invest in liquid assets and maintain an appropriate level of cash reserves to ensure that we can access our money when we need it.

We will consider investing in ethical stocks that align with our charitable mission and avoid those where possible that go against our charity’s aim.

We will measure the performance of our investments based on the total return, Consumer Prices Index (CPI) plus 4%, and other appropriate benchmarks. We will review our performance regularly and adjust our investment strategy as necessary.

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Reserves policy

As part of the annual planning and budget-setting cycle, the Board of Trustees review and approve the level of readily available reserves appropriate to the scale, complexity, and risk profile of BDP. The Finance and General Purposes Committee keep this under review. The provision made for lease dilapidation commitments increased to £216,300 (2023/24: £210,000).

The Board of Trustees’ policy is to retain accumulated unrestricted funds to provide continuity of service in the event of: late payment of funds; where contract payments are made in arrears; unexpected contingency; to enable BDP to compete in competitive procurement processes against much larger market ‘players’; and to sustain priority activities in line with the charity’s objectives. Recognising the added costs associated with the implementation of a new system in Bristol (including significant legal and HR costs) and the need to retain resources with which to run BDP if our contract was to unexpectedly end, the Board of Trustees has identified the need to retain unrestricted reserves necessary for 9 months operating costs. The Board has built up healthy reserves to allow for uncertainty and to support vital services not funded by our current contract (with reserves supporting, for example, the 50+, New Leaf and M32 services in 2024-5). We can clearly demonstrate that we retain sufficient resources to deliver services with confidence and to manage any negative impact on government spending, which remains the major source of the charity’s income.

With BDP producing a new strategy in 2025, we will want to direct some of our reserves to growing future endeavours, to further the charity’s objectives and minimise our reliance on core contracts.

Principal risks and uncertainties

The Board of Trustees considers exceptional risks routinely at its meetings when it receives reports of emerging or unforeseen risks. The main financial risk to the charity, which would constrain its ability to deliver services to people with alcohol and drug problems on the scale in which they are required, is loss of funding for our core contract, Bristol Horizons. BDP mitigates this risk by providing high quality and effective services which are valued by key partners, attractive to prospective commissioners, and credible and effective for people with alcohol or drug problems and people in those communities which are impacted by these.

BDP secured significant additional income in 2024-25 as a result of OHID funding and BCC’s Transformation programme. This year has seen the adoption of a “full-cost recovery” model as well as achieving a realistic margin on new monies in order that BDP can increase its resilience and improve its infrastructure.

We continue to take steps to diversify our funding base to increase resilience, while recognising that securing income on the scale required to deliver reliable services to vulnerable adults and children from sources other than the public sector is not realistic.

The charity’s main funding in 2024-25 derived from ROADS and Targeted Youth Services (TYS). ROADS is a fixed value contract, which was extended to 31 March 2025, at the Year Five funding value. The TYS contract has been extended to align with the ROADS contract to 31 March 2025, after which the two services will be commissioned as one entity.

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

BDP has developed a strong partnership consisting of national and local partners that contributed to the successful re-tender for Bristol substance use services, providing a degree of certainty over the next five years, with potential for further extensions of a further four years. We anticipate this successful bid will see BDP maintain similar levels of net income, workforce and range of services although the partnership structure will necessitate changes to organisational and operational structures.

Plans for future periods

BDP’s CEO will be producing a new strategy for the next 18 months, which will provide a strategic direction for BDP, focusing on; making BDP a great place to work, providing high quality services and innovating for the future.

Fundraising

BDP did not employ professional fundraisers or commercial participators during this or previous periods and therefore the provisions of the Charity (Protection and Social Investment) Act 2016 do not apply to the charity’s activities.

Statement of responsibilities of the trustees

The Trustees (who are also Directors of the charity for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charity and of the income and expenditure of the charity for that period. In preparing those financial statements the trustees required to:

select suitable accounting policies and then apply them consistently;
▪ observe the methods and principles in the Charities SORP; ▪ make judgements and accounting estimates that are reasonable and prudent;
state whether applicable UK accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements; and
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

The trustees responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with the Companies Act 2006. The trustees also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

there is no relevant audit information of which the charitable company's auditors are unaware; and
the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. trustees are members of the charity but this entitles them only to voting rights. trustees have no beneficial interest in the charity.

Auditors

Godfrey Wilson Limited were re-appointed as auditors to the charitable company during the year and have expressed their willingness to continue in that capacity.

Approved by the trustees on 10 November 2025 and signed on their behalf by

T Rice - Director and Chair

Independent auditors' report

To the members of

Bristol Drugs Project Limited

Opinion

We have audited the financial statements of Bristol Drugs Project Limited (the 'charity') for the year ended 31 March 2025 which comprise the statement of financial activities, balance sheet, statement of cash flows and the related notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

give a true and fair view of the state of the charity's affairs as at 31 March 2025 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and the provisions available for small entities, in the circumstances set out in note 5 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Independent auditors' report

To the members of

Bristol Drugs Project Limited

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the trustees’ report, which includes the directors’ report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
▪ the directors’ report included within the trustees’ report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors’ report included within the trustees’ report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of trustees’ remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit; or
the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies’ exemptions in preparing the trustees’ report and from the requirement to prepare a strategic report.

Responsibilities of the trustees

As explained more fully in the trustees’ responsibilities statement set out in the trustees’ report, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Independent auditors' report

To the members of

Bristol Drugs Project Limited

Our responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The procedures we carried out and the extent to which they are capable of detecting irregularities, including fraud, are detailed below:

(1) We obtained an understanding of the legal and regulatory framework that the charity operates in, and assessed the risk of non-compliance with applicable laws and regulations. Throughout the audit, we remained alert to possible indications of non-compliance.

(2) We reviewed the charity’s policies and procedures in relation to:

Identifying, evaluating and complying with laws and regulations, and whether they were aware of any instances of non-compliance;
Detecting and responding to the risk of fraud, and whether they were aware of any actual, suspected or alleged fraud; and
Designing and implementing internal controls to mitigate the risk of non-compliance with laws and regulations, including fraud.

(3) We inspected the minutes of trustee meetings.

(4) We enquired about any non-routine communication with regulators and reviewed any reports made to them.

(5) We reviewed the financial statement disclosures and assessed their compliance with applicable laws and regulations.

(6) We performed analytical procedures to identify any unusual or unexpected transactions or balances that may indicate a risk of material fraud or error.

(7) We assessed the risk of fraud through management override of controls and carried out procedures to address this risk. Our procedures included:

▪Testing the appropriateness of journal entries;
▪Assessing judgements and accounting estimates for potential bias;
▪Reviewing related party transactions; and

▪Testing transactions that are unusual or outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. Irregularities that arise due to fraud can be even harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

Independent auditors' report

To the members of

Bristol Drugs Project Limited

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charityʼs members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charityʼs members those matters we are required to state to them in an auditorʼs report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charityʼs members as a body, for our audit work, for this report, or for the opinions we have formed.

Date: 10 November 2025

Robert Wilson FCA (Senior Statutory Auditor)

For and on behalf of:

GODFREY WILSON LIMITED

Chartered accountants and statutory auditors 5th Floor Mariner House 62 Prince Street Bristol BS1 4QD

Bristol Drugs Project Limited

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 March 2025

Note Income from: Donations and legacies Charitable activities 4 Other trading activities Investments Total income Expenditure on: Raising funds Total expenditure 7 Net (loss) / gains on investments 9 Net income / (expenditure) Transfers between funds Net movement in funds 5 Reconciliation of funds: Total funds brought forward Total funds carried forward Charitable activities: provision of services	Unrestricted £ 37,332 2,200,830 2,305 131,569 2,372,036 (18,587) (1,938,590) (1,957,177) (66,600) 348,259 235,463 583,722 3,756,499 4,340,221	Restricted £ - 3,279,802 - - 3,279,802 - (3,358,003) (3,358,003) - (78,201) (235,463) (313,664) 339,630 25,966	2025 2024 Total Total £ £ 37,332 39,121 5,480,632 4,413,648 2,305 14,104 131,569 95,366 5,651,838 4,562,239 (18,587) (4,003) (5,296,593) (4,568,739) (5,315,180) (4,572,742) (66,600) 79,513 270,058 69,010 - - 270,058 69,010 4,096,129 4,027,119 4,366,187 4,096,129

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in note 16 to the accounts.

Bristol Drugs Project Limited

Balance sheet

At 31 March 2025

Note Fixed assets Tangible assets 8 Investments 9 Current assets Debtors 10 Current asset investments Cash at bank and in hand Liabilities Creditors: amounts falling due within 1 year 11 Net current assets Total assets less current liabilities Provisions for liabilities 12 Net assets 14 Funds 16 Restricted funds Unrestricted funds: Designated funds General funds Total charity funds	£ 588,363 1,132,884 516,180 2,237,427 (651,561)	2025 £ 333,165 2,663,456 2,996,621 1,585,866 4,582,487 (216,300) 4,366,187 25,966 38,311 4,301,910 4,366,187	2024 £ 93,063 2,143,141
			2,236,204 605,785 700,603 1,987,550
			3,293,938 (1,224,013)
			2,069,925
			4,306,129 (210,000)
			4,096,129
			339,630 54,668 3,701,831
			4,096,129

These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies' regime.

Approved by the trustees on 10 November 2025 and signed on their behalf by

Mike Lea

T Rice - Director and Chair M Lea - Treasurer

Bristol Drugs Project Limited

Statement of cash flows

For the year ended 31 March 2025

Cash flows from operating activities: Net movement in funds: Adjustments for: Dividends, interest and rents from investments Profit on the sale of fixed assets Gains on investments Depreciation Decrease in debtors Increase / (decrease) in creditors Increase in provisions Net cash provided by / (used in) operating activities Cash flows from investing activities: Dividends, interest and rents from investments Purchase of investments Purchase of tangible fixed assets Profit on the sale of fixed assets Net cash used in investing activities Decrease in cash and cash equivalents in the year Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the year Analysed as: Cash at bank and in hand Current asset investments Cash held in investment portfolio	2025 £ 270,058 (131,569) - 66,600 49,716 17,422 (572,452) 6,300 (293,925) 131,569 (1,138,000) (289,818) - (1,296,249) (1,590,174) 3,256,281 1,666,107 516,180 1,132,884 17,043 1,666,107	2024 £ 69,010 (95,366) (9,834) (79,513) 17,188 39,323 332,525 44,000
		317,333
		95,366 (1,479,500) (58,284) 9,834
		(1,432,584)
		(1,115,251) 4,371,532
		3,256,281
		1,987,550 700,603 568,128
		3,256,281

Analysis of changes in net debt

The charity has not provided an analysis of changes in net debt as it does not have any long term financing arrangements.

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

1. Company status

The company is a registered charity and a company limited by guarantee without share capital, incorporated in England and Wales. The guarantors are the council members to the extent of £1 each.

The address of the registered office is 11 Brunswick Square, Bristol, BS2 8PE.

2. Accounting policies

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. There are no material departures from the SORP and FRS 102.

The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value, unless otherwise stated in the relevant accounting policy note. The accounts are presented in sterling which is also the functional currency of the charity.

b) Going concern basis of accounting

The accounts have been prepared on the assumption that the charity is able to continue as a going concern, which the trustees consider appropriate. The charity holds unrestricted, general reserves of £4,301,910 and a cash balance of £516,180. There are no material uncertainties about the charity's ability to continue as a going concern.

c) Income

Incoming resources represent the amount derived from contracts, grants and donations receivable during the year. All income is credited to revenue when the charity is entitled to the income, any performance conditions have been met, it is probable that the income will be received and the amount can be measured reliably.

Many of the charity's funding streams, whilst having certain conditions attached which must be met to fulfil the charity's obligations, are actually contracts for service. Thus by providing the service for the year, the obligation attached to the contract is released with any residual deficit or benefit on the contract value being at the risk of or for the benefit of the charity. Income received in advance of provision of services under contracts is deferred until criteria for income recognition are met.

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

2. Accounting policies (continued)

c) Income (continued)

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

d) Expenditure and irrecoverable VAT

Expenditure is included in the financial statements on an accruals basis. Expenditure is charged directly to the provision of services wherever possible.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

e) Allocation of support and governance costs

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Governance costs are the costs associated with the governance arrangements of the charity, including the costs of complying with constitutional and statutory requirements and any costs associated with the strategic management of the charity’s activities. All costs are allocated between the expenditure categories of the statement of financial activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly, together with fair allocation of management and support costs on an employee basis. No costs are allocated to expenditure on raising funds on the basis that BDP incurs minimal costs through fundraising activities and these are discrete from other charitable operations.

f) Funds

Unrestricted general funds are available for use at the discretion of the board of trustees in furtherance of the general objectives of the charity.

Restricted funds are funds which have been given for a specific purpose by the donor or statutory body or by the purpose of the appeal in which the funds are raised. Expenditure which meets these criteria is charged to the fund, together with fair allocation of management and support costs on an employee basis.

Designated funds are unrestricted funds of the charity which the trustees have decided at their discretion to set aside to use for a specific purpose.

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

2. Accounting policies (continued)

g) Tangible fixed assets

Depreciation of fixed assets is calculated to write off their cost less any residual value over their estimated useful lives as follows:

Motor vehicles, fixtures, fittings and office equipment are depreciated on a straight line basis over 5 years.

Assets are capitalised where the cost exceeds £2,500. A full year’s depreciation is charged in the year of acquisition.

h) Investments

Listed investments traded on a recognised stock exchange are stated at fair value at the reporting date, which is deemed to be their market value. Any gain or loss, whether realised or unrealised, is taken to the Statement of Financial Activities.

Investments in associated companies are held at cost, less provision for any impairment.

i) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

j) Current asset investments

Current asset investments consist of cash held on deposit in interest bearing accounts. Such investments are measured at their fair value.

k) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

l) Creditors

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

m) Operating leases

Rentals paid under operating leases are charged to the statement of financial activities as they fall due.

n) Pensions

The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £59,674 (2024: £47,303). Contributions totalling £10,758 (2024: £10,662) were payable to the fund at the balance sheet date and are included in creditors.

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

2. Accounting policies (continued)

o) Provisions

A provision is recognised in the balance sheet when the charity has a present legal or constructive obligation as a result of a past event, that can be reliably measured and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognised at the best estimate of the amount required to settle the obligation at the reporting date.

p) Financial instruments

The charity only has financial assets and financial liabilities that qualify as basic financial instruments, being trade and other debtors and creditors. Basic financial instruments are initially recognised at transaction value, and are subsequently recognised at their settlement value. Any losses arising from impairment (‘doubtful debts’) are recognised in the statement of financial activities. No impairment losses were recognised in the current or prior year.

q) Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity’s accounting policies, which are described above, the board of trustees is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The following are the critical judgements and estimates that the trustees have made in the process of applying the charity’s accounting policies and that have the most significant effect on the amounts recognised in the financial statements.

Provisions for lease dilapidations are recognised when a reliable estimate of the outflow of future economic benefit which will be required to settle any future obligation can be made. Further detail is provided in note 12.

Key management personnel are considered to be the board of trustees and the senior management team. As trustees, the board of trustees is not remunerated. The remuneration of key management personnel is disclosed in note 6.

Delays in obtaining final grant and contract agreements mean there is a degree of judgment involved in determining when entitlement to accrued income is met.

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

3. Prior period comparatives: statement of financial activities

Income from: Donations and legacies Charitable activities Other trading activities Investments Total income Expenditure on: Raising funds Charitable activities Total expenditure Net gains on investments Net income / (expenditure) Transfers between funds Net movement in funds	Unrestricted funds £ 39,121 1,123,890 14,104 95,366 1,272,481 (4,003) (1,228,608) (1,232,611) 79,513 119,383 31,469 150,852	£ - 3,289,758 - - 3,289,758 - (3,340,131) (3,340,131) - (50,373) (31,469) (81,842) Restricted funds	2024 Total £ 39,121 4,413,648 14,104 95,366
			4,562,239
			(4,003) (4,568,739)
			(4,572,742)
			79,513
			69,010 -
			69,010

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

4. Income from charitable activities

Bristol City Council Bristol Missing Link Developing Health & Independence National Lottery Grant (Allotment) NHS BNSSG ICB (Vanguard) Second Step Housing University Hospitals Bristol & Weston NHS ( Other charitable income less than £15,000 Total income from charitable activities Prior period comparative BrisDoc Bristol City Council (ADDER & OHID) Bristol City Council (ROADS) Bristol City Council (SSMTR) Creative Youth Network Hepatitis C Next Link NHS BNSSG CCG (Vanguard) Rough Sleeping Drug Alcohol Treatment Grant (Shared Care & Outreach) Second Step University Bristol & Weston NHS Other charitable income less than £9,999 Total income from charitable activities	£ 1,961,272 35,502 64,864 19,975 28,389 24,218 43,397 23,213 2,200,830 £ 30,000 518,190 - 236,759 23,797 38,003 35,502 43,131 135,688 30,974 - 31,846 1,123,890 Unrestricted funds Unrestricted funds	Restricted funds £ 3,279,802 - - - - - - 3,279,802 Restricted funds £ - - 3,279,893 - - - - - - - 8,665 1,200 3,289,758	2025 Total £ 5,241,074 35,502 64,864 19,975 28,389 24,218 43,397 23,213
			5,480,632
			2024 Total £ 30,000 518,190 3,279,893 236,759 23,797 38,003 35,502 43,131 135,688 30,974 8,665 33,046
			4,413,648

Government grants

The charity receives government grants, defined as funding from The National Lottery Community Fund to fund charitable activities. The total value of such grants in the period ending 31 March 2025 was £19,975 (2024: £nil). There are no unfulfilled conditions or contingencies attaching to these grants in the current or prior year.

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

5. Net movement in funds

Net movement in funds are stated after charging:

Depreciation of tangible fixed assets Auditors' remuneration (exc VAT): Audit Other services Trustees' remuneration Trustees' reimbursed expenses Trustees' indemnity insurance Operating lease payments: Rent Equipment	2025 £ 49,716 9,100 1,400 Nil 97 808 126,596 3,991	2024 £ 17,188 8,450 315 Nil Nil 736 122,146 4,236

Trustee reimbursed expenses relates to subsistence costs for 1 trustee (2024: nil).

In common with other charities of our size and nature we use our auditors to assist with the preparation of the financial statements. Our auditors have also provided consultancy services to the charity during the year.

6. Salaries

Staff costs were as follows:

Gross salaries Employers national insurance Pensions	2025 £ 2,855,700 261,488 59,674 3,176,862	2024 £ 2,462,669 211,149 47,303
		2,721,121

Two employees (2024: two) earned a salary in the range of £60,000 - £70,000 per annum.

Included in gross salaries are redundancy and termination costs totalling £14,000 (2024: £6,000), comprising wholly of ex-gratia payments. Redundancy and termination costs have been funded from unrestricted general funds (note 16).

Average number of employees (full time equivalent) Average number of employees (headcount)	2025 No. 87 101	2024 No. 78
		93

The total remuneration of key management personnel (as defined in note 2 (q) above) amounted to £236,835 (2024: £250,396).

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

7. Expenditure on charitable activities

Staff costs External supervision Legal and professional Recruitment Salaries, employer's NI and pensions (note 6) Training and development Travel and subsistence Direct service costs Breaking Free/SARI Client service access and translation Client workshop Contingency management and client research Health care intervention Youth groups Needle and syringe programme Volunteer expenses Partner payments Payments to joint providers Premises costs Premises costs	Raising funds £ - - - - - - - - - - - - - - - - - - - -	Charitable activities £ 12,720 - 1,055 3,087,338 22,114 22,163 3,145,390 20,956 11,669 81,138 5,032 14,825 9,624 258,896 2,612 404,752 1,065,612 1,065,612 187,981 187,981	Support and governance costs £ - 4,213 - 89,524 1,719 1,023 96,479 - - - - - - - - - - - - -	2025 Total £ 12,720 4,213 1,055 3,176,862 23,833 23,186
				3,241,869
				20,956 11,669 81,138 5,032 14,825 9,624 258,896 2,612
				404,752
				1,065,612
				1,065,612
				187,981
				187,981

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

7. Expenditure on charitable activities (continued)

Other costs Audit fees Bank charges Depreciation Equipment hire Health, safety and welfare Insurance IT costs and support Marketing and events Non capital equipment Printing, postage and stationery Professional fees and consultancy Provisions for liabilities Subscriptions Telephone charges Sub-total Allocation of support and governance costs Total expenditure	Raising funds £ - - - - - - - 6,880 - - 11,707 - - - 18,587 18,587 - 18,587	Charitable activities £ - 769 49,716 6,695 - 22,326 18,533 29,430 10,587 77,636 38,375 771 19,770 274,608 5,078,343 218,250 5,296,593	Support and governance costs £ 10,920 - - 21,760 808 88,283 - - - - - - - 121,771 218,250 (218,250) -	2025 Total £ 10,920 769 49,716 6,695 21,760 23,134 88,283 25,413 29,430 10,587 89,343 38,375 771 19,770
				414,966
				5,315,180 -
				5,315,180

Total governance costs were £15,941 (2024: £14,341).

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

7. Expenditure on charitable activities (continued) Prior year comparative

Staff costs External supervision Legal and professional Recruitment Salaries, employer's NI and pensions (note 6) Temporary staff Training and development Travel and subsistence Direct service costs Breaking Free/SARI Client service access and translation Client workshop Contingency management and client research Health care intervention Youth groups Needle and syringe programme Volunteer expenses Partner payments Payments to joint providers Premises costs Premises costs	Raising funds £ - - - - - - - - - - - - - - - - - - - - -	Charitable activities £ 9,813 - 22,230 2,663,023 30,450 23,074 26,527 2,775,117 22,495 11,768 25,356 4,177 28,925 5,255 211,910 4,986 314,872 998,164 998,164 161,252 161,252	Support and governance costs £ - 3,438 - 58,098 - - 156 61,692 - - - - - - - - - - - - -	2024 Total £ 9,813 3,438 22,230 2,721,121 30,450 23,074 26,683
				2,836,809
				22,495 11,768 25,356 4,177 28,925 5,255 211,910 4,986
				314,872
				998,164
				998,164
				161,252
				161,252

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

7. Expenditure on charitable activities (continued) Prior year comparative (continued)

Other costs Audit fees Bank charges Depreciation Equipment hire Health, safety and welfare Insurance IT costs and support Marketing and events Non capital equipment Printing, postage and stationery Professional fees and consultancy Provisions for liabilities Subscriptions Telephone charges Sub-total Allocation of support and governance costs Total expenditure	Raising funds £ - - - - - - - - - - 4,003 - - - 4,003 4,003 - 4,003	Charitable activities £ - 870 17,188 4,236 12,578 19,334 40,815 7,772 27,730 11,465 43,286 44,000 785 16,707 246,766 4,496,171 72,568 4,568,739	Support and governance costs £ 10,140 - - - - 736 - - - - - - - - 10,876 72,568 (72,568) -	2024 Total £ 10,140 870 17,188 4,236 12,578 20,070 40,815 7,772 27,730 11,465 47,289 44,000 785 16,707
				261,645
				4,572,742 -
				4,572,742

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

8. Tangible fixed assets

Cost At 1 April 2024 Additions for the year Disposals At 31 March 2025 Depreciation At 1 April 2024 Charge for the year On disposals At 31 March 2025 Net book value At 31 March 2025 At 31 March 2024	Motor vehicles £ 73,351 - - 73,351 55,701 2,271 - 57,972 15,379 17,650	£ 350,661 289,818 (20,352) 620,127 275,248 47,445 (20,352) 302,341 317,786 75,413 Fixtures, fittings and computer equipment	Total £ 424,012 289,818 (20,352)
			693,478
			330,949 49,716 (20,352)
			360,313
			333,165
			93,063

9. Investments

Investments
Market value at 1 April 2024 Additions Gains / (losses) Market value at 31 March 2025 Cash held by investment manager Total investments at 31 March 2025	£ £ 1,559,013 16,000 1,138,000 - (66,600) - 2,630,413 16,000 17,043 - 2,647,456 16,000 Investments in Associates Listed investments	2025 £ 1,575,013 1,138,000 (66,600) 2,646,413 17,043 2,663,456	2024 £ 16,000 1,479,500 79,513
			1,575,013 568,128
			2,143,141

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

9. Investments (continued)

Investments at market value comprise:

Listed investments Cash held by investment manager pending reinvestment Investments in Associate	2025 £ 2,630,413 17,043 16,000 2,663,456	2024 £ 1,559,013 568,128 16,000
		2,143,141

Details of investments in associates undertakings

Details of the investments in which the group holds 20% or more of the nominal value of any class of share capital are as follows:

	Country of		Proportion of voting	rights
Undertaking	incorporation	Holding	and shares held
			2025	2024
Social Impact Bristol	England and Wales	Ordinary	33%	33%
Limited		Shares

The principal activity of Social Impact Bristol Limited is to work with some of Bristol's most entrenched rough sleepers. The address of its registered office is 5th Floor, 3 Thomas More Square, London, E1W 1YW.

Social Impact Bristol Limited’s contract with Bristol City Council ended on 31 March 2021 and the company ceased trading on that date. The Directors have commenced proceedings to wind up the company and a voluntary liquidator was appointed on 18 May 2023. Upon wind up, any remaining funds will be distributed to investors.

10. Debtors

Amounts falling due within 1 year Trade debtors Prepayments Other debtors Amounts falling due after more than 1 year Rent and deposits	2025 £ 443,601 142,624 - 586,225 2,138 588,363	2024 £ 569,503 33,861 283
		603,647 2,138
		605,785

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

11. Creditors

Amounts falling due within 1 year Trade creditors Accruals Other taxation and social security Deferred income (see below) Other creditors The movement in deferred income was as follows: Balance at beginning of year Released during the year Deferred during the year Balance at end of year	2025 £ 306,363 123,382 52,375 157,841 11,600 651,561 2025 £ 817,761 (724,195) 64,275 157,841	2024 £ 255,789 87,418 57,974 817,761 5,071
		1,224,013
		2024 £ 421,173 (348,496) 745,084
		817,761

Deferred income relates to income received in advance of delivery of services.

12. Provision for liabilities

Provision for lease dilapidation	2025 £ 216,300	2024 £ 210,000

Included within the leases for the charity's rented premises are dilapidation clauses. The trustees consider they are able to quantify the expected cost of the lease dilapidations, and have consequently included a provision of £216,300 (2024: £210,000) in the accounts.

13. Guarantees and other financial commitments

The charity had operating leases at the year end with total future minimum lease payments as follows:

Amount falling due: Within 1 year Within 1 - 5 years	2025 £ 40,163 7,708 47,871	2024 £ 69,301 63,441
		132,742

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

14. Analysis of net assets between funds

General funds 2025 £ Tangible fixed assets 333,165 Investments 2,663,456 Current assets 1,909,442 Current liabilities (387,853) Provisions (216,300) Total net assets at 31 March 2025 4,301,910 Prior year comparative General funds 2024 £ Tangible fixed assets 93,063 Investments 2,143,141 Current assets 1,914,393 Current liabilities (238,766) Provisions (210,000) Total net assets at 31 March 2024 3,701,831 Financial instruments at fair value Financial assets measured at fair value	Designated funds 2025 £ - - 302,019 (263,708) - 38,311 2024 £ - - 591,779 (537,111) - 54,668 Designated funds	Restricted funds 2025 £ - - 25,966 - - 25,966 2024 £ - - 787,766 (448,136) - 339,630 2025 £ 2,630,413 Restricted funds	Total funds 2025 £ 333,165 2,663,456 2,237,427 (651,561) (216,300)
			4,366,187
			Total funds 2024 £ 93,063 2,143,141 3,293,938 (1,224,013) (210,000)
			4,096,129
			2024 £ 1,559,013

15. Financial instruments at fair value

Financial assets measured at fair value comprise listed investments.

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

16. Movement in funds

Restricted funds ROADS APPS/SMART ROADS Complex Needs Veterans Total restricted funds Unrestricted funds Designated funds: Healthcare Coordinator ASB Treatment Engagement Creative Communities Dentaid Service Hepatitis C Engagement Worker Missing Link National Lottery - Allotment New Leaf Rapid Safe Inhalation Pipe Prevention Second Step Link Service Intensive Family Support Sub total designated funds Street Intervention Service ROADS Early Engagement & Intervention ROADS Substance Misuse Liaison	At 1 April 2024 £ - - 144,011 169,653 25,966 339,630 - - 13,700 26,686 2,695 6,132 - - 412 - - - 49,625	Income £ 257,429 666,908 980,991 1,374,474 - 3,279,802 38,118 86,912 164,566 - 43,397 35,502 19,975 28,389 6,536 24,218 90,763 21,650 560,026	£ (257,429) (666,908) (998,316) (1,435,350) - (3,358,003) (38,118) (68,573) (130,703) (19,010) (46,092) (28,157) (5,523) (40,352) (6,948) (24,218) (90,763) (21,650) (520,107) Expenditure	£ - - (126,686) (108,777) - (235,463) - (18,339) (47,563) - - - - 11,963 - - - - (53,939) Transfers between funds	Gains / (losses) £ - - - - - - - - - - - - - - - - - - -	£ - - - - 25,966 At 31 March 2025
						25,966
						- - - 7,676 - 13,477 14,452 - - - - -
						35,605

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

16. Movement in funds (continued)

Movement in funds (continued)
Unrestricted funds (continued) Designated funds (continued): Sub total brought forward Overdose Prevention Programme Physical Healthcare Programme Transformation Service Young Peoples Service Designated funds less than £10,000 Total designated funds General funds Total unrestricted funds Total funds Connect Substance Misuse Liaison	At 1 April 2024 £ 49,625 - - - - - 5,043 54,668 3,701,831 3,756,499 4,096,129	Income £ 560,026 70,000 196,204 18,107 1,129,851 142,144 16,776 2,133,108 238,928 2,372,036 5,651,838	£ (520,107) (75,633) (136,871) - (724,249) (160,995) (14,267) (1,632,122) (325,055) (1,957,177) (5,315,180) Expenditure	£ (53,939) 5,633 (59,333) (18,107) (405,602) 18,851 (4,846) (517,343) 752,806 235,463 - Transfers between funds	Gains / (losses) £ - - - - - - - - (66,600) (66,600) (66,600)	£ 35,605 At 31 March 2025
						- - - - - 2,706
						38,311
						4,301,910
						4,340,221
						4,366,187

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

16. Movement in funds (continued)

Purposes of restricted funds:

Recovery Orientated Alcohol & Drugs Service (ROADS):

APPS/SMART - After Prison Prescribing Service (APPS) provides rapid prescribing for people released from prison. CHART, delivered by partner BrisDoc HealthCare Services provides a rapid prescribing service for people who are homeless or discharged from hospital. This contract ended March
Complex Needs - Delivery of a Consultant Psychiatrist-led range of pharmacological and psychological support to people with most complex needs, who are alcohol or drug dependent, sub-contracted to Avon and Wiltshire Partnership Mental Health Trust. This contract ended March 2025
Early Engagement & Intervention delivering harm reduction services including needle and syringe programme, outreach, and work with non opiate users delivered by BDP and BBV interventions led by a nurse sub-contracted from Avon and Wiltshire Partnership Mental Health Trust (AWP) and a physical healthcare service delivered by a nurse sub-contracted from BrisDoc HealthCare Services. This contract ended March 2025 and the unspent
Substance Misuse Liaison delivering Opioid Substitution Treatment with GPs, community detox and alcohol detoxification. This contract ended March 2025 and the unspent funding was agreed by the Bristol City Council to transfer to General funds for future costs on contracts with no uplifts.

Veterans - Donation from the Youngwood Trust enabling continuation of the Veteran Support Worker role from May 2020. After reviewing the veterans support organisations capacity to engage during and after the covid restrictions, it was agreed with the donor to pause this activity until a later date, not yet decided.

Purposes of designated funds:

Healthcare Coordinator - A role that supports people facing health inequalities due to substance use, assertively engaging people into primary and secondary care services.

ASB Treatment Engagement - A service that offers drug and alcohol treatment to people who are engaged in anti-social behaviour in their community.

Creative Communities - Develop the engaging range of recovery initiatives and activities including a web-based platform. Fundraise and promote these activities on a one-year appointment.

Dentaid Service - A Partnership between BrisDoc, Dentaid and BDP with the purpose of providing monthly pop-up dental health clinics for people who struggle to get their dental health needs met in the community due to homelessness, drug/alcohol use and complex needs.

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

16. Movement in funds (continued)

Purposes of designated funds (continued):

Hepatitis C Engagement Worker - Partnership with Hep CU later, University Hospital Bristol Western and Gilead Research to fund a role that would engage and test people for Hepatitis C, working towards the WHO global strategy to reduce new infections.

Missing Link - Link worker role working with Next Link to decrease barriers for people suffering with domestic violence.

National Lottery - Allotment - To support BDP allotment and provide a growing project whilst being a specifically designed therapeutic, social space for support groups who use, or are in recovery from alcohol and drugs.

New Leaf Rapid - following a successful application through Vanguard (BNSSG Integrated Care Board), New Leaf Rapid has funding for 3 full time workers for 2 years. The pilot year is in Bristol and year 2 extended to South Gloucestershire and North Somerset. NLR works with Violence Reductions Units’ (Safer Options in Bristol), Education Inclusion Managers to harness a Drugs in School Pathway to reduce school exclusions for substance use or behaviours resulting from Children Affected By Substances trauma.

Safe Inhalation Pipe Prevention - Collaboration between London School of Hygiene and Tropical Medicine and BDP into research and evaluation on reducing health harms and increase service engagement for those who smoke crack cocaine in England.

Second Step Link Service- BDP employ and second a member of staff to the Second Step Link team. The Link Team supports people in Bristol who are street homeless or at imminent risk of homelessness, and who also experience severe emotional distress associated with a mental health problem.

Intensive Family Support - A service that intensively works with parents who are struggling with their drug and alcohol use.

Street Intervention Service - Now funded by Rough Sleeping Drug and Alcohol Treatment Grant (RSDATG), initially funded by ROADS within Bristol City Council’s Street Intervention Service (SIS). The SIS’s priority is to reduce Antisocial Behaviour through a combination of support and enforcement activity.

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

16. Movement in funds (continued)

Purposes of designated funds (continued):

Connect Substance Misuse Liaison - A service that connects people with a history of rough sleeping into community services and Opiate substitution therapy.

Overdose Prevention Programme - Cross-system service to provide strategic coordination and distribution of Naloxone by all participating agencies in Bristol, together with establishing and maintaining a training programme.

Physical Healthcare Program - Our nursing led service, delivered in partnership with Brisdoc, offers physical healthcare interventions (such as wound care, infection treatment and chronic health condition management) at our city centre health and harm reduction hub.

Transformation Service - The transformation programme is a programme of work being undertaken by Bristol City Council to make improvements to the drug and alcohol treatment system and work towards the aims set out by the Government's strategy. This includes raising numbers of people in treatment, supporting more people to seek treatment for alcohol use and reducing drug related deaths.

Young Peoples Service -Funded for one year by Supplementary grants to continue the targeted service offered previously under Targeted Youth Services, for young people who are using substances themselves and / or affected by parental substance misuse. The trustees have agreed to use General Funds for the shortfall of funding towards the performance of this service.

Designated funds less than £10,000 - These are funds received for specific services/projects ie. Youth Alcohol Drug Diversion; offers young people under the age of 18 arrested for first time possession of a substance controlled under the Misuse of Drugs Act, the opportunity to engage with a structured individual intervention as an alternative to a criminal justice disposal, Feeding Bristol; two grants received in the year for specific projects to supply food parcels to the most vulnerable clients and families.

Purposes of transfers between funds:

Transfer out of ROADS funds - Bristol City Council agreed for BDP to transfer the underspend from the ROADS contract to our reserves funds to be used for any future spend on substance use services for Bristol.

Remaining transfers between funds represent adjustments to designated funds.

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

16. Movement in funds (continued) Prior period comparative Restricted funds ADDER ROADS APPS/SMART ROADS Complex Needs Veterans Total restricted funds Unrestricted funds Designated funds: 50+ Get Back Out There ADDER Creative Communities Dentaid Service Hepatitis C Engagement Worker Missing Link National Lottery - New Roots New Leaf Rapid Safe Inhalation Pipe Prevention Second Step Link Service Special Allocation Service Sub total designated funds Street Intervention Service ROADS Substance Misuse Liaison ROADS Early Engagement & Intervention	At 1 April 2023 £ 31,469 - - 166,077 197,960 25,966 421,472 653 - - - 1,107 - 4,578 (5,720) 5,961 - - - 6,579	Income £ - 257,611 666,908 990,765 1,374,474 - 3,289,758 - 463,141 61,049 30,000 38,003 35,502 - 43,130 4,084 30,975 7,983 32,746 746,613	£ - (257,611) (666,908) (1,012,831) (1,402,781) - (3,340,131) (653) (426,096) (47,349) (3,314) (36,415) (29,370) (7,168) (37,410) (9,633) (30,975) (7,983) (32,746) (669,112) Expenditure	£ (31,469) - - - - - (31,469) - (37,045) - - - - 2,590 - - - - - (34,455) Transfers between funds	Gains / (losses) At 31 March 2024 £ £ - - - - - - - 144,011 - 169,653 - 25,966 - 339,630 - - - - - 13,700 - 26,686 - 2,695 - 6,132 - - - - - 412 - - - - - - - 49,625

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2025

16. Movement in funds (continued) Prior period comparative (continued) Unrestricted funds (continued) Designated funds (continued): Sub total brought forward Targeted Youth Service Transformation Service Young Peoples Service Youth Alcohol Drug Diversion Designated funds less than £9,999 Total designated funds General funds Total unrestricted funds Total funds Connect Substance Misuse Liaison	At 1 April 2023 £ 6,579 - - - - - - 6,579 3,599,068 3,605,647 4,027,119	Income £ 746,613 102,942 23,797 96,932 142,144 3,264 7,228 1,122,920 149,561 1,272,481 4,562,239	£ (669,112) (102,942) (29,574) (96,932) (155,843) (3,264) (2,185) (1,059,852) (172,759) (1,232,611) (4,572,742) Expenditure	£ (34,455) - 5,777 - 13,699 - - (14,979) 46,448 31,469 - Transfers between funds	Gains / (losses) £ - - - - - - - - 79,513 79,513 79,513	At 31 March 2024 £ 49,625
						- - - - - 5,043
						54,668
						3,701,831
						3,756,499
						4,096,129

17. Called up share capital

There is no share capital as the company is limited by guarantee. In the event of the charity being wound up the liability in respect of the guarantee is limited to £1 per member of the charity as stated in the Memorandum and Articles of Association.

Bristol Drugs Project Limited Report and Audited Financial Statements 31 March 2025

Bristol Drugs Project Limited

Contents

Bristol Drugs Project Limited

Reference and administrative details

Bristol Drugs Project Limited

Reference and administrative details

For the year ended 31 March 2025

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Structure, governance and management Governing document

Board of Trustees (Directors)

Recruitment, appointment and changes to Board of Trustees

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Board of Trustees induction and training

Board of Trustees’ committees

Senior Leadership Team (SLT)

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Partnership working

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Risk management

Objectives and activities Charitable purpose

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Achievements & performance – delivering public benefit

Who we provide public benefit for

How we provide public benefit

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Research partnerships:

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Achievements and performance

10 years of Creative Communities

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

The Transformation Programme

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Increasing rollout of Naloxone across Bristol

Reaching Hepatitis C Micro-Elimination Status

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Collaboration with Dentaid

Key performance data

Financial review

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Principal funding sources

Investment policy

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Reserves policy

Principal risks and uncertainties

Bristol Drugs Project Limited

Report of the trustees

For the year ended 31 March 2025

Plans for future periods

Fundraising

Statement of responsibilities of the trustees

Bristol Drugs Project Limited